Non-Hodgkin's Lymphomas and Chronic Lymphocyctic Leukemia
Badoux X et al. A Phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. Proc ASCO 2010;Abstract 6508.
Chen C et al. A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Proc ASH 2008;Abstract 44.
Coiffier B et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 2008;26(16):2767-78. Abstract
Czuczman MS et al. Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL). Proc ASCO 2010;Abstract 8042.
Ferrajoli A et al. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL). Proc ASH 2008;Abstract 45.
Fowler NH et al. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin’s lymphoma. Proc ASCO 2010;Abstract 8036.
Friedberg JW et al. Bendamustine, bortezomib and rituximab in patients (pts) with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): A multicenter Phase II clinical trial. Proc ASH 2009;Abstract 924.
Friedberg JW et al. Follicular lymphoma in the United States: First report of the national LymphoCare study. J Clin Oncol 2009;27(8):1202-8. Abstract
Morschhauser F et al. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: A multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS). Cancer 2010;116(18):4299-308. Abstract
O’Connor OA et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre Phase 2 clinical trial. Br J Haematol 2009;145(1):34-9. Abstract
Pettengell R et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. Proc ASCO 2010;Abstract 8005.
Rummel MJ et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Proc ASH 2009;Abstract 405.
Salles GA et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. Proc ASCO 2010;Abstract 8004.
Multiple Myeloma
Attal M et al. Lenalidomide maintenance after transplantation for myeloma. Proc ASCO 2010;Abstract 8018.
Hainsworth JD et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: A phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008;113(4):765-71. Abstract
Harousseau JL et al. The role of complete response in multiple myeloma. Blood 2009;114(15):3139-46. Abstract
Mateos MV et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28(13):2259-66. Abstract
Mateos MV et al. A prospective, multicenter, randomized trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years. Proc ASH 2009;Abstract 3.
McCarthy PL et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. Proc ASCO 2010;Abstract 8017.
Palumbo A et al. A Phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Proc ASH 2009;Abstract 613.
Rajkumar SV et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010;11(1):29-37. Abstract
Richardson PG et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline. Br J Haematol 2009;144(6):895-903. Abstract
San Miguel JF et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359(9):906-17. Abstract
Breast Cancer
Brufsky A et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. San Antonio Breast Cancer Symposium 2009;Abstract 42.
Eiermann W et al, on behalf of the BCIRG005 investigators. BCIRG 005 main efficacy analysis: A phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC → T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. San Antonio Breast Cancer Symposium 2008;Abstract 77.
Goss PE et al. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. San Antonio Breast Cancer Symposium 2009;Abstract 13.
Hurvitz SA et al. Final results of a Phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. San Antonio Breast Cancer Symposium 2009;Abstract 6094.
Miles D et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc ASCO 2008;Abstract LBA1011.
Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76. Abstract
Ranpura V et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: A meta-analysis. Am J Hypertens 2010;23(5):460-8. Abstract
Robert NJ et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. Proc ASCO 2009;Abstract 1005.
Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2009;Abstract 62.
Yardley DA et al. Preliminary progression free survival and SPARC tumor correlatives from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab paclitaxel. Poster. San Antonio Breast Cancer Symposium 2008;Abstract 5116.
Non-Small Cell Lung Cancer
Akerley WL et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. Proc ASCO 2008;Abstract 8043.
Fukuoka M et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). ASCO 2009;Abstract 8006.
Hirsh R et al. Final safety results of BO17704 (AVAiL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). ASCO 2009;Abstract 8039.
Kwak EL et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. Proc ASCO 2009;Abstract 3509.
Le Chevalier T et al. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). Proc ASCO 2008;Abstract 7507.
Leltzmann MF et al. Prospective study of physical activity and lung cancer by histologic type in current, former, and never smokers. Am J Epidemiol 2009;169(5):542-53. Abstract
Miller VA et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Proc ASCO 2009;Abstract LBA8002.
Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57. Abstract
Olaussen KA et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355(10):983-91. Abstract
Parsons A et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: Systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569. Abstract
Patel JD et al. Treatment rationale and study design for the pointbreak study: A randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:252-6. Abstract
Scagliotti GV et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51. Abstract
Shih J et al. A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). Proc ASCO 2009;Abstract 8013.
Yang C et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): A preliminary report. Proc ASCO 2009;Abstract 8062.